Inflammation and Atherosclerosis: The End of a Controversy
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
oes inflammation matter in coronary artery disease?Is it a driving force in atherosclerosis or merely an epiphenomenon?Is there space for novel therapies besides those targeting cholesterol?The CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study), which was presented at the European Society of Cardiology meeting in Barcelona a few weeks ago, provides answers to these important questions.Indeed, the results of this trial open up a new avenue for cardiovascular prevention.Atherosclerosis, the underlying pathology in most cases of myocardial infarction, ischemic stroke, and ischemic gangrene, is a disease of complex genesis that has remained controversial for decades.Clinical and experimental studies have provided unequivocal evidence for an etiologic role of cholesterol and also offered strong support for a pathogenic role of inflammation. 1 By targeting cholesterol, blood pressure, and cigarette smoking, cardiovascular prevention has become one of the great success stories in medicine.We have witnessed a reduction in the incidence of myocardial infarction by ≈40% in large parts of the world during the past 2 decades, and a substantial part of this decrease can be ascribed to preventive medicine. 1Cholesterol-lowering statin therapy reduces the incidence of major adverse cardiovascular events by 25% to 50% in individuals with elevated low-density lipoprotein cholesterol and has become standard therapy for a large segment of the population in the Western world.The success of statins made us wonder whether we could realistically expect any further improvement in cardiovascular prevention.This attitude gained further support when it was found that statins also have anti-inflammatory properties.Although residual risk after myocardial infarction remains high, many clinicians and investigators did not see any reason for further development of cardiovascular prevention.The results of the CANTOS study demand a reassessment of the situation. 2ANTOS is a randomized, double-blind secondary prevention trial in 10 061 patients with prior myocardial infarction and elevated levels of the inflammation marker, high-sensitive C-reactive protein (>2 mg/L). 2 In all, 80% of the study participants were treated for hypertension, 40% had diabetes mellitus, and >90% were on statin therapy.They were randomized into 4 groups that received canakinumab, a human monoclonal antibody to the inflammatory cytokine, interleukin (IL)-1β at 3 different dosages, or placebo.Canakinumab is currently used clinically in some rare autoinflammatory conditions and as a second line of treatment in rheumatoid diseases.As expected, canakinumab reduced high-sensitive C-reactive protein levels; it had no substantial effect on plasma lipids. 2 The primary end point of the study was the first occurrence of myocardial infarction, stroke, or cardiovascular death.Canakinumab reduced this end point significantly, from 4.5 per 100 person-years in the placebo group to 3.9 in the groups receiving ≥150 mg antibody per dose. 2 This translated to a 15% relative reduction Inflammation and AtherosclerosisThe End of a Controversy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Self-citationRidker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
Cited by
The changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873
Ridker, P. M., Libby, P., MacFadyen, J. G., Thuren, T., Ballantyne, C., Fonseca, F., Koenig, W., Shimokawa, H., Everett, B. M., & Glynn, R. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy310 · Cited by 544
Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences
Boehncke, W.-H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00579 · Cited by 307
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260
Novel antiatherosclerotic therapies
Libby, P., & Everett, B. M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310958 · Cited by 145
Metadata
- Authors
- Hansson, G. K.
- Venue
- Circulation
- Published
- 2017-11-14
- Volume
- 136
- Issue
- 20
- Pages
- 1875-1877
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2754580435
- Cited by
- 149
- References
- 4
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammation and Atherosclerosis: The End of a Controversy. https://app.cochat.ai/papers/10.1161/circulationaha.117.030484
- The paper
- Hansson, G. K. (2017). Inflammation and Atherosclerosis: The End of a Controversy. Circulation. https://doi.org/10.1161/circulationaha.117.030484
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.